Mr. Thomas Smeenk reports

HEMOSTEMIX ANNOUNCES LEAD ORDER OF $1,500,000 AND THE FULL REPAYMENT OF $2,500,000 CONVERTIBLE DEBENTURE

Hemostemix Inc.'s chairman, Peter Lacey, has provided the company with a lead order for a non-brokered private placement in the amount of $1.5-million for units at 10 cents. Each unit will consist of one common share and one warrant. Each warrant may be exercised by the holder to acquire one common share at 15 cents for a period of two years from the closing date.

The company will use $1.25-million of the $1.5-million to repay 100 per cent of a convertible debenture in the amount of $2.5-million. The closing of the lead order will take place as a first tranche of a total placement of up to $2.5-million for units at 10 cents. All securities issued in connection with the offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside of Canada.

Certain directors of the company are participating in the offering, which constitutes a related-party transaction within the meaning of Multilateral Instrument 61-101 (Protection of Minority Security Holders in Special Transactions) and the policies of the TSX Venture Exchange. The company is relying upon the exemptions from the formal valuation and minority shareholder approval requirements pursuant to sections 5.5(b) and 5.7(1)(a), respectively, of MI 61-101 on the basis that the company is not listed on a specified stock exchange and, at the time the offering was agreed to, neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the transaction insofar as it involves an interested party (within the meaning of MI 61-101) in the offering, exceeds 25 per cent of the company's market capitalization calculated in accordance with MI 61-101.

Further to the March 5, 2025, news release announcing the sale of 15 ACP-01 therapy convertible debentures for proceeds of $708,605 ($517,230 (U.S.)) subject to the approval of the TSX Venture Exchange, the company confirms that the conversion price of each TCD is at 15.5 cents.

The company confirms that there is no material fact or material change about the company that has not been generally disclosed.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum technology pioneer award, the company has developed, has patented, and is scaling and selling autologous (patient's own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in nine peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase 2 clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared with a five-year mortality rate of 60 per cent in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0 per cent mortality, cessation of pain and wound healing in 83 per cent of patients followed for up to 4.5 years as a midpoint result.

We seek Safe Harbor.